Filtered By:
Condition: Pregnancy
Infectious Disease: COVID-19
This page shows you your search results in order of date.
Order by Relevance | Date
Total 35 results found since Jan 2013.
Why It Took So Long to Finally Get an RSV Vaccine
Respiratory syncytial virus (RSV) can dangerously compromise breathing, especially for infants and the elderly. But there has been no vaccine to prevent it—until today. On May 3, the U.S. Food and Drug Administration (FDA) approved the first vaccine against RSV, from GlaxoSmithKline (GSK), to prevent respiratory disease in people ages 60 and older. The Centers for Disease Control’s vaccine committee will make formal recommendations in June about who should receive the vaccine, but GSK says it currently has enough doses to vaccinate eligible people beginning this fall.
In studies involving 25,000 people that GSK...
Source: TIME: Health - May 3, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthscienceclimate Source Type: news
Patterns of maternal gestational weight gain in association with allergic diseases in offspring: A prospective cohort study
CONCLUSIONS: Maternal GWG pattern characterised by rapid GWG earlier in pregnancy was associated with a lower risk of atopic allergy in offspring.PMID:36938832 | DOI:10.1111/1471-0528.17448
Source: BJOG : An International Journal of Obstetrics and Gynaecology - March 20, 2023 Category: OBGYN Authors: Lixia Lin Xi Chen Li Huang Chunrong Zhong Meng Wu Weiming Wang Huanzhuo Wang Sen Yang Xiyu Cao Guoping Xiong Xuefeng Yang Liping Hao Guoqiang Sun Nianhong Yang Source Type: research
Local Immune Responses in Placentas of Women with COVID-19 SARS Complicated Pregnancy Increase with Each Trimester
This study assesses the features of local immune responses in placentas of women with COVID-19.
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Galyna Yeryomenko, Lawrence DuBuske, Myhaylo Myrosnuchenko Source Type: research
Science ’s 2022 Breakthrough of the Year: A telescope’s golden eye sees the universe anew
html { scroll-behavior: smooth; } .news-article-content--featured>.bodySection>.mb-2x:not(:first-of-type) { display: none; } h3 { scroll-margin-top: 5rem; } .parent-section h3, .subsection h3 { font-size: 1.375rem; line-height: 1.875rem; } .news-article-content-footer h2 { display: none; } .toc img { padding-bottom: 16px; transition: opacity .25s; } .toc img:hover { opacity: 60%; } .toc .image-grid img { padding-bottom: 16px; padding-top: 16px; } .image-grid .news-article__figure__image__wrapper:before, .image-grid .news-article__figure__image__wrapper:after { display: none; } .news-article-content sectio...
Source: ScienceNOW - December 15, 2022 Category: Science Source Type: news
A Positive HIV Test Shattered His Dreams of Serving in the U.S. Army. Now He ’ s Suing
One cold winter morning in 2008, 8-year-old Isaiah Wilkins decided to try on his mother’s National Guard uniform, something he always wanted to do. She was away at training in Texas, but she kept an extra uniform at home in Temple, Georgia.
Young Isaiah climbed up to the attic of his parents’ single-story house and spotted the blue 30-gallon bin where his mother stored her military clothes. He unclicked the clips on the sides, lifted the lid, and rummaged through the neatly organized items. After carefully shuffling through a few patches and her combat boots, he spotted her uniform.
[time-brightcove not-tgx=...
Source: TIME: Health - December 1, 2022 Category: Consumer Health News Authors: Jordan Gonsalves Tags: Uncategorized HIV/AIDS Military Source Type: news
‘Extremely satisfying’: Scientist’s insight powers new RSV vaccine for infants
Barney Graham, a former scientist at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), was thrilled yesterday when
Pfizer announced encouraging results
from an experimental vaccine that could protect against a major childhood killer. In a press release, the company said immunizing pregnant women
*
with its vaccine against respiratory syncytial virus (RSV) protected their babies from severe disease for 6 months. If the full results of its clinical trial bear out that promise, the vaccine could spare millions of infants worldwide from RSV-related hospitalization, reduce lasting lung damage f...
Source: Science of Aging Knowledge Environment - November 2, 2022 Category: Geriatrics Source Type: research
Monoclonal antibody treatment of COVID-19 in a pregnant woman with common variable immunodeficiency
Since the first reported case of COVID-19, infections due to the virus have ranged from mild to severe. Patients with inborn errors of immunity are thought to be at increased risk for infections such as COVID-...
Source: Allergy, Asthma and Clinical Immunology - October 16, 2022 Category: Allergy & Immunology Authors: Babak Aberumand, Ramy Kamal, Brock McKinney and Stephen Betschel Tags: Case report Source Type: research
Top Local Changemakers Addressing Health Equity Gaps Across the U.S. Named Johnson & Johnson Health Equity Innovation Challenge Awardees
NEW BRUNSWICK, N.J., June 14, 2022 – After an extensive search for the top changemakers in six key U.S. cities, Johnson & Johnson today announced the 14 awardees of its Health Equity Innovation Challenge. The awardees, who possess lived experience and a deep understanding of the communities they serve, were selected for their work in generating solutions to help close racial health and mortality gaps in six cities where Black and Brown individuals experience significant health inequities: Chicago, Detroit, Los Angeles, New Orleans, New York City and Philadelphia.The Health Equity Innovation Challenge was created by J...
Source: Johnson and Johnson - June 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
Lancet Respir Med. 2022 May 23:S2213-2600(22)00088-1. doi: 10.1016/S2213-2600(22)00088-1. Online ahead of print.ABSTRACTBACKGROUND: Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in preventing progression to mechanical ventilation or death in hospitalised patients with COVID-19.METHODS: In this randomised, double-blind, double placebo-controlled trial, patients were enrolled at 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites)...
Source: Respiratory Care - May 26, 2022 Category: Respiratory Medicine Authors: Cameron R Wolfe Kay M Tomashek Thomas F Patterson Carlos A Gomez Vincent C Marconi Mamta K Jain Otto O Yang Catharine I Paules Guillermo M Ruiz Palacios Robert Grossberg Michelle S Harkins Richard A Mularski Nathaniel Erdmann Uriel Sandkovsky Eyad Almasri Source Type: research
10 Black Americans Who Have Led COVID-19 Response
By The Editorial Team,
IntraHealth InternationalFebruary 22, 2022Meet 10 Black American leaders who are shaping local and national COVID-19 response. These scientists, researchers, policymakers, teachers, and more have seen first-hand how the pandemic exacerbates racial disparities in health. In the US, Black Americans have died from COVID-19 at1.4 times the rate of white people.Today we’re highlighting these leaders as they work to protect their communities and inform our global response to the pandemic.Christopher BarnesAssistant professor, Department of Biology at Stanford UniversityWhen COVID-19 began, Bar...
Source: IntraHealth International - February 17, 2022 Category: International Medicine & Public Health Authors: kseaton Tags: COVID-19 Health Workers Source Type: news
Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine
NEW BRUNSWICK, N.J., December 15, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for use of the Company’s COVID-19 vaccine as a booster for adults aged 18 and older at least two months after primary vaccination with a single-shot of the Johnson & Johnson COVID-19 vaccine, and as a ‘mix and match’ booster following primary vaccination with an approved two-shot mRNA COVID-19 vaccine regimen (known as heterologous boosting). “We are pleased with today’s Positiv...
Source: Johnson and Johnson - December 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
An immunologist's perspective on anti-COVID-19 vaccines
Purpose of review
Antisevere acute respiratory syndrome-corona virus 2 (SARS-CoV-2) vaccines may provide prompt, effective, and safe solution for the COVID-19 pandemic. Several vaccine candidates have been evaluated in randomized clinical trials (RCTs). Furthermore, data from observational studies mimicking real-life practice and studies on specific groups, such as pregnant women or immunocompromised patients who were excluded from RCTs, are currently available. The main aim of the review is to summarize and provide an immunologist's view on mechanism of action, efficacy and safety, and future challenges in vaccination...
Source: Current Opinion in Allergy and Clinical Immunology - November 8, 2021 Category: Allergy & Immunology Tags: PRIMARY IMMUNE DEFICIENCY DISEASE: Edited by M. Teresa de la Morena and Stephen Jolles Source Type: research
COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety
AbstractTo date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Although the benefit –risk profile of these vaccines was proven to be largely favourable in the general population, evidence in special cohorts initially excluded from the pivotal trials, such as pregnant and breastfeeding women, children/adolescents, immunocompromised people and persons with a history of allergy or p revious SARS...
Source: Drug Safety - November 5, 2021 Category: Drugs & Pharmacology Source Type: research
